Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute on Drug Abuse (NIDA) |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00104598 |
This is a randomized study of message framing in individuals beginning a smoking cessation program utilizing bupropion SR and brief counseling, videos, and pamphlets.
Condition | Intervention |
---|---|
Tobacco Use Disorder |
Drug: Bupropion |
Study Type: | Interventional |
Study Design: | Treatment, Parallel Assignment |
Official Title: | Framing Messages for Smoking Cessation With Buproprion |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Exclusion Criteria:
United States, Connecticut | |
Substance Abuse Treatment Unit | |
New Haven, Connecticut, United States, 06519 |
Principal Investigator: | Stephanie O'Malley, Ph.D. | Substance Abuse Treatment Unit |
Study ID Numbers: | NIDA-13334-6, P50-13334-6 |
Study First Received: | March 1, 2005 |
Last Updated: | November 3, 2005 |
ClinicalTrials.gov Identifier: | NCT00104598 History of Changes |
Health Authority: | United States: Federal Government |
Dopamine Uptake Inhibitors Neurotransmitter Agents Tobacco Use Disorder Psychotropic Drugs Disorders of Environmental Origin Smoking Dopamine |
Mental Disorders Bupropion Substance-Related Disorders Dopamine Agents Antidepressive Agents, Second-Generation Antidepressive Agents |
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Tobacco Use Disorder Physiological Effects of Drugs Psychotropic Drugs Disorders of Environmental Origin Pharmacologic Actions |
Mental Disorders Therapeutic Uses Bupropion Substance-Related Disorders Dopamine Agents Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |